1 / 6

Hepatitis Studies

Hepatitis Studies. Shyam Kottilil M.D., Ph.D. Laboratory of Immunoregulation National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Bethesda, MD. Hepatitis C and HIV coexist in the US. IVDU. 100. 5. HCV. 90%. 80. 4.

effie
Download Presentation

Hepatitis Studies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hepatitis Studies Shyam Kottilil M.D., Ph.D. Laboratory of Immunoregulation National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Bethesda, MD

  2. Hepatitis C and HIV coexist in the US IVDU 100 5 HCV 90% 80 4 60 3 Number affected (millions) Percentage All HIV+ 40 2 33% HIV 20 1 0 0 Population Population Sulkowski MS, Mast EE, Seeff, LB et al. Hepatitis C Virus Infection as an Opportunistic Disease in Persons infected with Human Immunodeficiency Virus. Clin Infect Dis. 2000;30:577-84.

  3. Washington, D.C. Our Nation’s Capital 3%=18000 HIV+ 1.8%=12000 HCV+

  4. Establishment of Hepatitis Clinics Average Incidence Rate per 100,000 Population 0 - 25.0 25.1 – 50.0 50.1 – 75.0 75.1 – 100.0 100.1 – 125.0 Numbers found below each ward refer to the rate of newly reported HIV cases per 100,000 population. Rates were calculated using 2000 Census data. For 16% of cases, ward information was not available and therefore not displayed on this map.

  5. Hepatitis Treatment Protocols-DC-PFAP TLR7 Phase 1 HCV-DAA Natural History Anti-fibrosis GS-7977+RBV HCV DAA Tx Anti-fibrosis Jan June June Sept Sept Dec Mar Mar Anti-fibrosis IFN and RBV FREE Tx Peg+RBV+PI (Boc) TLR7 PHASE 1 HCV-DAA

  6. Washington, D.C. Our Nation’s Capital Most Effective HIV Program Most Effective Hepatitis Program

More Related